NCT01789398已完成3 期
Double Blind Randomized Study to Assess the Efficacy of BF2.649 Compared to Placebo in add-on to Sodium Oxybate in the Treatment of Narcoleptic Patients With Residual Excessive Daytime Sleepiness (EDS) During 8 Weeks
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Bioprojet
- 入组人数
- 51
- 试验地点
- 1
- 主要终点
- Efficacy on EDS as measured by ESS ( Epworth Sleepiness Scale)
研究概览
简要总结
This is a multicentric international phase III, double blind randomized study assessing efficacy and safety in parallel group of BF2.649 (pitolisant) compared to placebo in add-on to sodium oxybate of narcoleptic patients with residual Excessive Daytime Sleepiness (EDS) during 8 weeks
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males or females, aged 18 years old and over.
- •Patients with a diagnosis of narcolepsy according to the International Classification of Sleep Disorders (ICSD-2) criteria
- •Patients treated with sodium oxybate (Xyrem®) with a stable dosage for at least 2 months prior to the trial.
- •Patients complaining of residual EDS
- •Patient should be free of non authorized drugs or discontinue any psychostimulant medication at least 3 weeks before randomization (V2).
- •Females of child-bearing potential must use a medically accepted effective method of birth control, agree to continue this method for the duration of the study and be negative to serum pregnancy test performed at the screening visit. Females should not be breast-feeding patient.
- •In the opinion of the investigator, the patient must have adequate support to comply with the entire study requirements as described in the protocol (e.g. transportation to and from trial site, self rating scales, drug compliance, scheduled visits, etc).
- •Patient must have voluntarily expressed a willingness to participate in this study, signed and dated an informed consent prior to beginning this protocol required procedures.
排除标准
- •Psychiatric and neurological disorders, other than narcolepsy/cataplexy, such as moderate or severe psychosis or dementia, bipolar illness, severe anxiety, clinical severe depression (BDI ≥ 16) with suicidal risk (item G BDI > 0), or depression treated for less than 8 weeks, history of seizure disorder or other problem that in the investigator's opinion would preclude the patient's participation and completion of this trial or comprise reliable representation of subjective symptoms.
- •Patients working in an occupation requiring variable shift work or routine night shifts.
- •Patients with an untreated sleep apnea disorder (defined as an apnea index > 10/h or an apnea/hypopnea index>15/h) or who have any other cause of daytime sleepiness.
- •Use of hypnotics, tranquilizers, sedating antihistamines, psychostimulants for the treatment of EDS (amphetamine and amphetamine-like CNS stimulants, modafinil, methylphenidate or others), benzodiazepines, anticonvulsants or clonidine will not be accepted at least 3 weeks before randomization (V2) and during study.
- •Current or recent (within one year) history of a substance abuse or dependence disorder including alcohol abuse as defined in Diagnostic and Statistical Manual of Mental Disorders (DSM-IV).
- •Other active clinically significant illness, including unstable cardiovascular, or neoplasic pathology which could interfere with the study conduct or counter-indicate the study treatments or place the patient at risk during the trial or compromise the study participation.
- •Patient with a known history of long QTc syndrome (e.g. syncope or arythmia) or presenting any significant serious abnormality of the ECG (e.g. recent myocardial infarction), or QTc interval strictly higher than 450 ms (electrocardiogram Bazett's corrected).
- •Patients with Severe Hepatic Impairment or with Severe Renal Impairment, or with any other significant abnormality in the physical examination or clinical laboratory results.
- •Known hypersensitivity to the tested treatment including active substance and excipients.
- •Patients participating in an other study and the use of any investigational therapy within the 30 days prior to the entry in this study.
- •Patient without any medical care insurance
研究组 & 干预措施
BF2.649 (pitolisant)
Experimental
BF2.649 (5mg, 10mg, 20mg or 40mg) in capsules
干预措施: BF2.649 (Drug)
placebo
Placebo Comparator
Placebo of BF2.649 (5mg, 10mg, 20mg or 40mg) in capsules
干预措施: BF2.649 (Drug)
结局指标
主要结局
Efficacy on EDS as measured by ESS ( Epworth Sleepiness Scale)
时间窗: 8 weeks
based on the ESS score change from baseline to final visit.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
3 期
Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy as First Line Treatment in Patients With Advanced Non-Squamous NSCLCNon-Squamous Non-Small Cell Neoplasm of LungNCT03912389Biocad292
进行中（未招募）
3 期
A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung CancerLimited-Stage Small Cell Lung CancerNCT05353257Shanghai Henlius Biotech511
尚未招募
3 期
to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)Triple Negative Breast CancerNCT04301739Shanghai Henlius Biotech522
已完成
3 期
A Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP)Acute PyelonephritisComplicated Urinary Tract InfectionNCT02486627Achaogen, Inc.609
已完成
3 期
A Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study of the Efficacy and Safety of QL1701 Plus Docetaxel Versus Herceptin® Plus Docetaxel as First Line Therapy in Patients With HER2-positive Metastatic Breast CancerBreast CancerNCT05629949Qilu Pharmaceutical Co., Ltd.474